Wells Fargo’s Takeda Pharmaceutical TAK Stock Holding History

Wells Fargo’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-35,000	Closed	-$477K	–	7786
2021 Q4	$477K	Hold	35,000	–	–	﹤0.01%	4702
2021 Q3	$573K	Sell	35,000 -2,000	-5%	-$33.6K	﹤0.01%	4590
2021 Q2	$623K	Hold	37,000	–	–	﹤0.01%	4502
2021 Q1	$676K	Buy	+37,000	New	+$666K	﹤0.01%	4512

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo's TAK Position: Q1 2026 in Review

Wells Fargo increased its Takeda Pharmaceutical (TAK) stake by 7.1% in Q1 2026, buying an estimated $1.33M and bringing the position to 1,136,022 shares worth $21M. The position accounts for ﹤0.01% of the portfolio, ranked #1478.

Wells Fargo first reported a position in TAK in Q4 2018 and has held it in 30 quarters since. The position peaked at $46M in Q1 2021. 360 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Wells Fargo held 1,136,022 shares of Takeda Pharmaceutical worth $21M as of Q1 2026.
Wells Fargo bought 75,561 Takeda Pharmaceutical shares in Q1 2026, an estimated $1.33M.
Takeda Pharmaceutical made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #1478 holding.
Wells Fargo first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 30 quarters since.
Wells Fargo's Takeda Pharmaceutical position peaked at $46M in Q1 2021.
360 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.